Stack
Retatrutide with MOTS-c
A triple incretin agonist next to a mitochondrial peptide, on the argument that losing weight fast is easier than losing it well. The second half has never finished a human trial.
Start with the concern, because it is a real one. Rapid weight loss on an incretin agonist is not all fat. Holding onto lean mass and metabolic capacity through it is a genuine problem, and the trial protocols address it with protein intake and resistance training, not with a second compound.
MOTS-c is the second compound people reach for anyway. It is a peptide encoded in mitochondrial DNA, and animal work associates it with AMPK signalling, insulin sensitivity and exercise capacity. That maps onto the concern almost too neatly.
It has no completed human efficacy trial. The animal work is interesting and the mechanism is not invented. But the step from "associated with metabolic regulation in mice" to "protects metabolic capacity in a person losing weight on retatrutide" is the entire claim, and nobody has tested any of it.
As with every stack of this shape, the incretin agonist accounts for the weight change. Run both, like the result, and what you have learned about is retatrutide.
The schedule
Commonly run, not recommended16 weeks. Doses are what sources describe rather than what we advise — where a source gave a range we show the range instead of choosing a number inside it.
| Compound | Dose | How often | Weeks |
|---|---|---|---|
| RetatrutideEarly human trialsThe established half. Triple incretin agonist, titrated upward over months. | 1 mg–12 mg | Weekly · MonGastrointestinal effects track the dose. That is why every trial climbed slowly instead of starting at target. | 1–16 |
| MOTS-cPreclinicalThe speculative half. Added on animal work associating it with metabolic regulation. | 5 mg–10 mg | Weekly · ThuDescribed frequencies run from twice weekly to weekly. Every one of them is extrapolated from rodent studies rather than established in people. | 1–16 |
Things worth knowing
- The problem this stack goes after, lean mass and metabolic capacity during rapid loss, already has a well-evidenced answer, and it is not a compound. Enough protein and resistance training. A peptide does not substitute for either.
- Nothing in either record describes an interaction. Nobody has studied the combination. That is not the same as having studied it and found it clear.
- MOTS-c has no human pharmacokinetic data, so there is no basis for saying what a given subcutaneous dose achieves.
- Both compounds are sold as research chemicals with no pharmacopoeial standard.
Related
Questions
- Does MOTS-c preserve muscle on a GLP-1?
- It has not been tested. The mechanism is plausible and the animal work is real, but no human study has looked at MOTS-c during incretin-driven weight loss. The things known to preserve lean mass in that situation are protein intake and resistance training.
- Can the two be injected on the same day?
- People separate them by convention rather than for any established reason. There is no described interaction, and no study of timing to point at either.
- Is MOTS-c the same as an NAD+ booster?
- No, though they get discussed together constantly. MOTS-c is a peptide associated with AMPK signalling. NAD+ is a coenzyme. The pathways are related the way most metabolic pathways are related. That is not the same as one being a version of the other.
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.